Gallium Oxodotreotide

CHEMBL262135 Phase 4 Approved Protein
Half-Life
β€”
Bioavailability
β€”
Protein Binding
β€”
Molecular Weight
β€” g/mol
LogP
β€”
Phase
4

A radioactive imaging agent used in PET scans to detect neuroendocrine tumors throughout the body. It attaches to specific receptors found on the surface of these tumors.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A radioactive imaging agent used in PET scans to detect neuroendocrine tumors throughout the body. It attaches to specific receptors found on the surface of these tumors.

Yes, Gallium Oxodotreotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

  • ChEMBL β€” European Bioinformatics Institute (EBI). CHEMBL262135. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.